SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced ...
Preliminary data demonstrate FPI-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer (mCRPC), including those who received prior ...
HAMILTON, ON and BOSTON, Oct. 12, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results